• 1
    Zitvogel LTM,Borg C,Trinchieri G. Dendritic cell-NK cell cross-talk: regulation and physiopathology. Curr Top Microbiol Immunol 2006: 298; 15774.
  • 2
    Pinzon-Charry A,Maxwell T,Lopez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005; 83: 45161.
    Direct Link:
  • 3
    Yang L,Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004; 92: 1327.
  • 4
    Chapatte L,Ayyoub M,Morel S,Peitrequin A-L,Levy N,Servis C,Van den Eynde BJ,Valmori D,Levy F. Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses. Cancer Res 2006; 66: 54618.
  • 5
    Davis ID,Chen Q,Morris L,Quirk J,Stanley M,Tavarnesi ML,Parente P,Cavicchiolo T,Hopkins W,Jackson H,Dimopoulos N,Tai TY, et al. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother 2006; 29: 499511.
  • 6
    Ribas A. Update on immunotherapy for melanoma. J Nat Compr Cancer Netw (J NCCN) 2006; 4: 68794.
  • 7
    Rietschel C. Immunotherapy of melanoma. Hematol Oncol Clin North Am 2006; 20: 75166.
  • 8
    Rosenberg SA,Sherry RM,Morton KE,Yang JC,Topalian SL,Royal RE,Kammula US,Restifo NP,Hughes MS,Schwarz SL,Ngo LT,Mavroukakis SA, et al. Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother 2006; 29: 22431.
  • 9
    Smith SG,Patel PM,Porte J,Selby PJ,Jackson AM. Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Clin Cancer Res 2001; 7: 425361.
  • 10
    Geiger J,Hutchinson R,Hohenkirk L,McKenna E,Chang A,Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000; 356: 1163.
  • 11
    Nestle FO,Alijagic S,Gilliet M,Sun Y,Grabbe S,Dummer R,Burg G,Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 32832.
  • 12
    Sullenger BA,Gilboa E. Emerging clinical applications of RNA. Nature 2002; 418: 2528.
  • 13
    Lizee G,Radvanyi LG,Overwijk WW,Hwu P. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res 2006; 12: 2359s2365s.
  • 14
    Bennaceur K,Popa I,Portoukalian J,Berthier-Vergnes O,Peguet-Navarro J. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol 2006; 18: 87986.
  • 15
    Schnurr M,Toy T,Stoitzner P,Cameron P,Shin A,Beecroft T,Davis ID,Cebon J,Maraskovsky E. ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood 2003; 102: 61320.
  • 16
    Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006; 6: 47683.
  • 17
    Cheadle EJ,Jackson AM. Bugs as drugs for cancer. Immunology 2002; 107: 109.
  • 18
    Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 2004; 16: 2734.
  • 19
    Palsson-McDermott EM,O'Neill LA. Signal transduction by the lipopolysaccharide receptor. Toll-like receptor-4. Immunology 2004; 113: 15362.
  • 20
    Luft T,Luetjens P,Hochrein H,Toy T,Masterman KA,Rizkalla M,Maliszewski C,Shortman K,Cebon J,Maraskovsky E. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol 2002; 14: 36780.
  • 21
    Puig-Kroger A,Relloso M,Fernandez-Capetillo O,Zubiaga A,Silva A,Bernabeu C,Corbi AL. Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 2001; 98: 217582.
  • 22
    Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5: 52131.
  • 23
    Peng JC,Hyde C,Pai S,O'Sullivan BJ,Nielsen LK,Thomas R. Monocyte-derived DC primed with TLR agonists secrete IL-12p70 in a CD40-dependent manner under hyperthermic conditions. J Immunother 2006; 29: 60615.
  • 24
    Wang S,Hong S,Yang J,Qian J,Zhang X,Shpall E,Kwak LW,Yi Q. Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006; 108: 40717.
  • 25
    Wang S,Yang J,Qian J,Wezeman M,Kwak LW,Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006; 107: 24329.
  • 26
    Kotera Y,Shimizu K,Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of Antigen(s) in dendritic cell-based immunization. Cancer Res 2001; 61: 81059.
  • 27
    Basu S,Binder RJ,Suto R,Anderson KM,Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-{kappa}B pathway. Int Immunol 2000; 12: 153946.
  • 28
    Shurin GV,Shurin MR,Bykovskaia S,Shogan J,Lotze MT,Barksdale EM,Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001; 61: 3639.
  • 29
    Peng JC,Abu Bakar S,Richardson MM,Jonsson JJ,Frazer IH,Nielsen LK,Morahan G,Thomas R. IL10 and IL12B polymorphisms each influence IL-12p70 secretion by dendritic cells in response to LPS. Immunol Cell Biol 2006; 84: 22732.
    Direct Link:
  • 30
    Gajewski TF,Meng Y,Blank C,Brown I,Kacha A,Kline J,Harlin H. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006; 213: 13145.
  • 31
    Takahashi A,Kono K,Ichihara F,Sugai H,Fujii H,Matsumoto Y. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 2004; 53: 54350.
  • 32
    Kalinski P,Vieira PL,Schuitemaker JHN,de Jong EC,Kapsenberg ML. Prostaglandin E2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001; 97: 34669.
  • 33
    Nakahara T,Uchi H,Urabe K,Chen Q,Furue M,Moroi Y. Role of c-Jun N-terminal kinase on lipopolysaccharide induced maturation of human monocyte-derived dendritic cells. Int Immunol 2004; 16: 17019.
  • 34
    Yang DD,Conze D,Whitmarsh AJ,Barrett T,Davis RJ,Rincon M,Flavell RA. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998; 9: 57585.
  • 35
    Hirschfeld M,Ma Y,Weis JH,Vogel SN,Weis JJ. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 2000; 165: 61822.
  • 36
    Lu HT,Yang DD,Wysk M,Gatti E,Mellman I,Davis RJ,Flavell RA. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. Embo J 1999; 18: 184557.
  • 37
    Yi AK,Yoon JG,Yeo SJ,Hong SC,English BK,Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol 2002; 168: 471120.
  • 38
    Xie J,Qian J,Yang J,Wang S,Freeman Iii ME,Yi Q. Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp Hematol 2005; 33: 56472.
  • 39
    Caparros E,Munoz P,Sierra-Filardi E,Serrano-Gomez D,Puig-Kroger A,Rodriguez-Fernandez JL,Mellado M,Sancho J,Zubiaur M,Corbi AL. DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood 2006; 107: 39508.
  • 40
    Nakahara T,Moroi Y,Uchi H,Furue M. Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. J Dermatol Sci 2006; 42: 111.
  • 41
    Aiba S,Manome H,Nakagawa S,Mollah ZUA,Mizuashi M,Ohtani T,Yoshino Y,Tagami H. p38 mitogen-activated protein kinase and extracellular signal-regulated kinases play distinct roles in the activation of dendritic cells by two representative Haptens, NiCl2 and 2,4-dinitrochlorobenzene. J Invest Dermatol 2003; 120: 3909.
  • 42
    Nakagawa S,Ohtani T,Mizuashi M,Mollah ZU,Ito Y,Tagami H,Aiba S. p38 mitogen-activated protein kinase mediates dual role of ultraviolet B radiation in induction of maturation and apoptosis of monocyte-derived dendritic cells. J Invest Dermatol 2004; 123: 36170.
  • 43
    Liu E,Law HK,Lau YL. Insulin-like growth factor I promotes maturation and inhibits apoptosis of immature cord blood monocyte-derived dendritic cells through MEK and PI 3-kinase pathways. Pediatr Res 2003; 54: 91925.
  • 44
    Escobar A,Lopez M,Serrano A,Ramirez M,Perez C,Aguirre A,Gonzalez R,Alfaro J,Larrondo M,Fodor M,Ferrada C,Salazar-Onfray F. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol 2005; 142: 55568.
  • 45
    Gattinoni L,Powell DJ,Jr,Rosenberg SA,Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 38393.
  • 46
    Yu JS,Liu G,Ying H,Yong WH,Black KL,Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64: 49739.
  • 47
    Vilella R,Benitez D,Mila J,Lozano M,Vilana R,Pomes J,Tomas X,Costa J,Vilalta A,Malvehy J,Puig S,Mellado B, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother 2004; 53: 6518.
  • 48
    Allen LF,Sebolt-Leopold J,Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003; 30: 10516.
  • 49
    LoRusso PM,Adjei AA,Varterasian M,Gadgeel S,Reid J,Mitchell DY,Hanson L,DeLuca P,Bruzek L,Piens J,Asbury P,Van Becelaere K, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 528193.
  • 50
    Rinehart J,Adjei AA,Lorusso PM,Waterhouse D,Hecht JR,Natale RB,Hamid O,Varterasian M,Asbury P,Kaldjian EP,Gulyas S,Mitchell DY, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22: 445662.